Ocriplasmin Approved by FDA to Treat Vitreomacular Adhesion
July 31, 2012
We’ve previously monitored developments with respect to ThromboGenics ocriplasmin for treatment of vitreomacular adhesion.
Last Thursday, an FDA panel recommended ThromboGenics NV’s ocriplasmin as a treatment for vitreomacular adhesion. The panel concluded that the injectable drug, marketed under the brand name Jetrea, helped enough people in clinical trials to warrant a favorable review, despite evidence of adverse effects including eye pain, swelling and blurred vision.
Click here for the full release (PDF).
You might also enjoy...
- ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
- Will Microplasmin Injections Transform Treatment of Vitreomacular Adhesion (Traction) and Macular Hole?
- ThromboGenics Completes Patient Enrollment in Microplasmin Trial
- ThromboGenics Launches JETREA® in United States for Non-Surgical Treatment of Vitreomacular Adhesion
- ThromboGenics Announces Testing of Medical Treatment for Vitreomacular Adhesions Underway
Jump down to form below to submit your own comments